Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of Multi-antibody cocktail therapy as prophylaxis before exposure to the SARS-CoV-2 virus or as treatment for those already infected

Trial Profile

A clinical study of Multi-antibody cocktail therapy as prophylaxis before exposure to the SARS-CoV-2 virus or as treatment for those already infected

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2020

At a glance

  • Drugs Multi antibody cocktail therapy Regeneron Pharmaceuticals (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Mar 2020 New trial record
    • 17 Mar 2020 According to an Regeneron Pharmaceuticals media release, this study is expected to begin by early(beginning) summer 2020.

Trial Overview

Purpose

This study will evaluate Multi-antibody cocktail therapy as prophylaxis before exposure to the SARS-CoV-2 virus or as treatment for those already infected.

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections prevention, treatment -

Subjects

  • Subject Type patients & volunteers
  • Sex male & female

Trial Details

Organisations

  • Affiliations Regeneron Pharmaceuticals

Trial Dates

Other Details

  • Design prospective
  • Phase of Trial Phase I
  • Location USA
  • Focus Therapeutic Use

Interventions

Drugs Route Formulation
Multi antibody cocktail therapy Regeneron PharmaceuticalsPrimary Drug Parenteral
-

Multi-antibody cocktail therapy

Trial History

Event Date Event Type Comment
20 Mar 2020 New trial record New trial record Updated 20 Mar 2020
17 Mar 2020 Other trial event According to an Regeneron Pharmaceuticals media release, this study is expected to begin by early(beginning) summer 2020. Updated 20 Mar 2020

References

  1. Regeneron Pharmaceuticals. Regeneron Announces Important Advances in Novel COVID-19 Antibody Program. Media-Rel 2020;.

    Media Release
Back to top